Neuroblastoma patient-derived xenograft cells cultured in stem-cell promoting medium retain tumorigenic and metastatic capacities but differentiate in serum

Camilla U. Persson1, Kristoffer von Stedingk2, Daniel Bexell3, My Merselius1, Noémie Braekeveldt1, David Gisselsson1, Marie Arsenian-Henriksson4, Sven Pählman1 & Caroline Wigerup1

Cultured cancer cells serve as important models for preclinical testing of anti-cancer compounds. However, the optimal conditions for retaining original tumor features during in vitro culturing of cancer cells have not been investigated in detail. Here we show that serum-free conditions are critical for maintaining an immature phenotype of neuroblastoma cells isolated from orthotopic patient-derived xenografts (PDXs). PDX cells could be grown either as spheres or adherent on laminin in serum-free conditions with retained patient-specific genomic aberrations as well as tumorigenic and metastatic capabilities. However, addition of serum led to morphological changes, neuronal differentiation and reduced cell proliferation. The epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) were central for PDX cell proliferation and MYCN expression, and also hindered the serum-induced differentiation. Although serum induced a robust expression of neurotrophin receptors, stimulation with their cognate ligands did not induce further sympathetic differentiation, which likely reflects a block in PDX cell differentiation capacity coupled to their tumor genotype. Finally, PDX cells cultured as spheres or adherent on laminin responded similarly to various cytotoxic drugs, suggesting that both conditions are suitable in vitro screening models for neuroblastoma-targeting compounds.

Neuroblastoma is a pediatric solid tumor of the sympathetic nervous system with an unmet need of novel treatment approaches for children with high-risk, metastasizing disease1. Neuroblastoma is a prototypical tumor type for studying tumor cell differentiation. The overall tumor differentiation stage, as scored by the expression levels of neuronal sympathetic marker genes, strongly correlates to clinical stage and patient outcome, where indolent tumors are generally more differentiated than aggressive tumors5. Histopathological assessment of neuroblastoma cell differentiation status is commonly performed as part of the clinical diagnostic procedure1 and the differentiating agent isotretinoin is part of standard-of-care therapy for children with high-risk neuroblastoma.

Human cancer cell lines are widely used as preclinical models to test novel drugs for cancer therapy. Despite their historical importance for understanding basic tumor biological questions, it is still uncertain how well cancer cell lines represent the primary tumor4. Traditionally, cancer cell lines have been established in serum-containing medium, which seems to select for fast growing cell types that do not fully resemble the in vivo situation. Serum-grown cells also differ phenotypically and genetically compared to their original tumor4,5.

1Translational Cancer Research, Lund University Cancer Center at Medicon Village, Lund University, Lund, Sweden. 2Department of Pediatrics, Clinical Sciences, Lund University, Lund, Sweden. 3Department of Clinical Genetics, Lund University, Department of Pathology, University and Regional Laboratories, Lund, Sweden. 4Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-171 77, Stockholm, Sweden. Correspondence and requests for materials should be addressed to C.W. (email: caroline.wigerup@med.lu.se)
and in vivo models based on xenografted cell lines rarely recapitulate the clinical course seen in patients. Thus, the usefulness of these models to evaluate potential new anti-cancer agents can be questioned, especially if these agents aim to target invasive and metastatic growth. There is a general need for establishing in vitro and in vivo tumor models. Neuroblastoma cell lines established in serum-containing medium have been available for more than 40 years and they have been essential for molecular characterization of defined aberrant pathways in neuroblastoma. They have also served as models of in vivo growth and treatment responses when cultured as xenografts in immune-deficient mice. However, the fact that xenografted neuroblastoma cell lines do not show robust metastatic growth, despite being established from aggressive, metastatic tumors, indicates that they do not fully mimic the tumors they derive from.

Patient-derived xenografts (PDXs), i.e. tumor cells or tissue pieces immediately engrafted in mice without any prior in vitro culture step, generally results in tumors that more closely reflect the primary tumors they were derived from as compared to xenografts based on classical cell lines.8,9 We recently established and characterized orthotopic neuroblastoma PDXs from high-risk patients and demonstrated that neuroblastoma PDXs maintain and recapitulate patient tumor characteristics.10,11 Importantly, the orthotopic PDXs metastasize to clinically relevant sites, including bone marrow.10 Tumor cells derived from PDXs can further be cultured as spheroids in stem-cell promoting medium with retained tumor-initiating and metastasizing capacity.

Here we report a comprehensive characterization of two MYCN amplified neuroblastoma PDX-derived cell lines, named LU-NB-2 and LU-NB-3. The PDX cells were routinely cultured as spheres under conditions initially optimized for growing neural stem cells. The same conditions were recently used for establishing neuroblastoma tumor initiating cells12 and here we tested whether serum-free conditions were more optimal for culturing LU-NB-2 and LU-NB-3 cells as compared to serum conditions. We observed that serum induced adherent growth of PDX cells and also sympathetic neuronal differentiation with an accompanied downregulation of MYCN expression and activity. Furthermore, serum-culture led to a significant downregulation of TERT complex genes. Spheroid cultures, however, present multiple drawbacks when e.g. screening for drugs; it is labor intensive and cellular heterogeneity can arise due to non-vascularized 3D growth and oxygen/nutrient deficiency in sphere centers. To facilitate future drug screens we therefore investigated conditions promoting monolayer culture, without affecting tumor-initiating and metastasizing capacities. The PDX cells could be grown as monolayer on recombinant human laminin without inducing significant alteration of the phenotype or in vivo behavior. The laminin-attached and sphere-cultured PDX cells, respectively, responded similarly to cytotoxic drugs, suggesting that both models are suitable in vitro systems for future drug screening.

Results

Neuroblastoma PDX cells retain metastatic capacity and patient-specific genomic aberrations following prolonged in vitro culturing. Previously, we reported that cells isolated from neuroblastoma PDXs can grow as neurospheres in stem-cell promoting medium (SC medium) (ref. 10 and Fig. 1a). Here we have further characterized cells isolated from PDX #2 and PDX #3, established from high-risk MYCN amplified neuroblastomas.10 The corresponding cell lines LU-NB-2 and LU-NB-3 are thus MYCN amplified and express typical neuroblastoma markers, as shown previously10 and here by NCAM (also known as CD56) and NSE expression as well as chromogranin A (CHGA) and tyrosine hydroxylase (TH) protein expression, thereby confirming their neuroblastoma origin (Fig. 1a–c). Orthotopic injection of different numbers of LU-NB-2 cells revealed that 10⁶ and 10⁴ cells gave rise to tumors in all mice, whereas 10² cells did not result in a visible tumor 1 year after injection (Supplementary Table S1) (due to ethical reasons, mice could not be kept longer). Orthotopic injection of 10⁶ LU-NB-3 cells gave rise to tumors in 3 out of 4 mice (Supplementary Table S1). PDX cell-derived tumors exhibited strong NCAM staining and heterogeneous expression of TH and Ki67 positive tumor cells (Fig. 1d).

Metastasis to lungs, liver and bone marrow were detected in tumor-bearing animals as shown by NCAM staining (Fig. 1e and Supplementary Fig. S1). Other overt serum concentration dependent effects were morphological differentiation (Fig. 2a and Supplementary Fig. S1). Addition of serum induced cell attachment of both LU-NB-2 and LU-NB-3 cells was explored by comparing short-term serum-grown PDX cells and serum-free cultured cells. Addition of serum induced cell attachment of both LU-NB-2 and LU-NB-3 cells (Fig. 2a and Supplementary Fig. S2a). Other overt serum concentration dependent effects were morphological differentiation and reduced cell numbers (Fig. 2a, f and Supplementary Fig. S2a). The attached cells showed neurite outgrowth and a robust increase in TH expression, both at mRNA and protein level, suggesting serum-driven differentiation (Fig. 2a–c and Supplementary Fig. S2a–c). In addition, mRNA and protein expression of other sympathetic neuronal markers including CHGA, SYP and SCG214, also increased (Fig. 2b, c and Supplementary Fig. S2b, c). The majority of differentiation markers was induced in a serum-concentration dependent manner in both LU-NB-2 and LU-NB-3 cells, however LU-NB-2 cells were less responsive to serum (Fig. 2a–c and Supplementary
This could potentially reflect the fact that PDX #2 was established from relapsed disease while PDX #3 was established prior to treatment. The expression of genes associated with an immature sympathetic nervous system phenotype, e.g. NOTCH1, NOTCH3 and HEY1 was downregulated in response to serum (Fig. 2d). Furthermore, serum led to an increased number of cells in G0/G1 phase at the expense of S/G2/M phase cells (Fig. 2e). There was no increase in the sub G0/G1 fraction as determined by flow cytometry, indicating that the
reduced cell number in serum was not due to cell death, a result corroborated by trypan blue staining (Fig. 2f). Continued growth in 10% serum for up to 6 weeks revealed that the cells survived, were still differentiated but with stagnating growth rates (Supplementary Fig. S2d,e). Taken together, LU-NB-2 and LU-NB-3 cells cultured under serum-free conditions maintain a less differentiated, proliferative cell phenotype while serum reduces proliferation and induces neuronal differentiation.

The neurotrophins NGF and NT-3 and their cognate receptors, TrkA and TrkC, are required for terminal differentiation of proliferating, non-transformed sympathetic neuroblasts. In neuroblastoma, high TrkA and TrkC expression is associated with low stage and less aggressive disease. The TRKA (also known as NTRK1) and TRKC (also known as NTRK3) expression increased robustly in serum-cultured LU-NB-3 cells (Fig. 2g), further supporting our conclusion that serum induces sympathetic differentiation. The obligatory co-receptor subunit of high affinity neurotrophin receptors is expressed in these cells, although at low levels (Fig. 2g). Interestingly, treating serum-cultured LU-NB-3 cells with NT-3 or NGF alone or in combination did not further increase the expression of TH, DBH or SCG2 (Supplementary Fig. S2f) nor did it enhance the serum-induced morphological differentiation. Cultured neuroblastoma cells expressing TRKA or TRKC are not resistant.

Figure 2. Serum-induced differentiation of PDX cells. LU-NB-3 cells were cultured in stem cell (SC) medium, 2% serum or 10% serum for 7 days unless other specified (a–g). (a) LU-NB-3 cells grown in SC medium (top panel), 2% serum (middle panel) or 10% serum (lower panel). Scale bars, 100 μm. (b,c) Expression of neuronal markers and MYCN at mRNA (b) and protein (c) level. (d) mRNA expression of markers associated with immature SNS phenotype. (e) Cell cycle analysis (72h). Representative data from 1 experiment is shown (n = 3). (f) Live cells (red bars) and dead cells (white bars) determined by trypan blue staining (72h). (g) Expression of neurotrophin receptor genes at the mRNA level. Error bars represent ± SEM from 3 independent analyses. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001; Student’s t test.
to neurotrophin stimulation, per se, as exemplified by NGF or NT-3 treated TRKA or TRKC overexpressing SH-SY5Y cells, although neurotrophin treatment in those cells did not induce terminal differentiation25,26. In line with reported data obtained from established neuroblastoma cell lines27, we propose that also the PDX cells lack the capacity to terminally differentiate.

**MYCN, telomerase complex genes and neuroblastoma PDX cell differentiation.** RNA sequencing of LU-NB-3 cells cultured in either serum-free or serum-containing medium revealed a general induction of a sympathetic neuronal phenotype at serum conditions as exemplified by increased expression of DBH, TH, PHOX2A, BCL2, MAOA and NSG1 (Fig. 3a). Furthermore, gene ontology analysis revealed a significant enrichment of neuronal differentiation in the samples of serum-cultured cells (Fig. 3b,c and Supplementary File S1). Interestingly, MYCN was the top downregulated gene in serum-cultured LU-NB-3 cells, showing over 9-fold decrease in mRNA expression level (Fig. 3d). This result was further supported by decreased protein levels (Fig. 2c and Supplementary Fig. S2c). Gene set enrichment analysis (GSEA) revealed a significant enrichment of genes regulated by MYCN in serum-free cultured cells (Fig. 3e and Supplementary File S2).

MYCN inhibition has previously been proposed to promote neuroblastoma cell differentiation, and we therefore treated LU-NB-3 cells with the MYC-MAX inhibitor 10058-F4. Treatment with 10058-F4 led to decreased MYCN protein, verifying MYCN inhibition (Fig. 3f). At mRNA level, treatment with 60 μM 10058-F4 for 72 h led to a modest upregulation of TH but had little or no effect on SCG2, TRKA and NOTCH1 expression, indicating that MYCN inhibition promotes differentiation of neuroblastoma PDX cells to a limited extent (Fig. 3g).

Tumor cells are characterized by high proliferation and are dependent on active telomerase to circumvent shortening of chromosomal ends. Because MYC can induce TERT expression28, we asked whether downregulation of MYCN and reduced proliferation in serum was coupled to decreased expression of TERT. Interestingly, TERT and other components of the telomerase complex, including TERC, DKC1, GARI and NHP2, were all downregulated in serum-grown LU-NB-3 cells (Fig. 3h). The snorRNPs DKC1, GARI and NHP2 have been shown to be important for telomerase activity in neuroblastoma29. A signature score based on these markers correlates with terminal aberrations and is an independent predictor of poor prognosis in neuroblastoma23,24.

**The SC medium growth factors EGF and bFGF decrease serum-induced differentiation.** For serum culture conditions we excluded the growth factors EGF and bFGF. These are two important components of stem-cell promoting medium previously shown to support expansion of neural stem cells by symmetrical division25. Withdrawal of EGF and bFGF from SC medium led to lower cell numbers and lowered MYCN levels in LU-NB-3 cells (Fig. 4a,b). However, this did not induce differentiation as determined by TH expression levels (Fig. 4b). Furthermore, addition of EGF and bFGF to serum-containing medium led to a less pronounced differentiating effect of added serum (Fig. 4b). Thus, our data suggest that EGF and bFGF are important for sustained proliferation of neuroblastoma PDX cells and that these factors diminish serum-induced differentiation.

Glucocorticoid receptor signaling has been reported to promote differentiation of neuroblastoma cells26. Since serum contains glucocorticoids we tested if 10% lipid-free, charcoal-stripped serum would induce differentiation. This condition did not promote cellular attachment or morphological differentiation, yet the expression of differentiation markers was still induced and MYCN levels decreased (Fig. 4c–e). We hypothesized that charcoal-stripped serum might still contain protein-bound corticosteroids able to induce the expression of differentiation markers and therefore measured the amount of steroids in regular and charcoal-stripped serum. Charcoal-stripped serum was principally free of steroids (Supplementary Table S2), suggesting that glucocorticoid signaling is not responsible for upregulation of differentiation markers at serum culture conditions.

**Serum-induced differentiation of PDX cells is reversible.** As we did not observe further differentiation by neurotrophin treatment we asked whether the serum-induced differentiation was reversible. LU-NB-3 cells were cultured in 10% serum medium for 7 days and then transferred back to SC medium for 4 days (Fig. 4f). This led to an increased proliferation and MYCN levels, and reduced expression of TH and SYP (Fig. 4g–i). Thus, the cellular differentiation induced by serum is reversible, which is in line with the observation that the PDX cells could not be terminally differentiated.

We next asked whether neuroblastoma cells that have been cultured in serum for decades would convert to a less differentiated phenotype in serum-free medium. We explored this by growing SK-N-BE(2)C cells for 7 and 14 days in either standard serum-containing or SC medium. SK-N-BE(2)C cells cultured in SC medium presented features25,27,28. The neuroblastoma PDX cells, however, adhered poorly to this substrate. A screening of laminin isoforms synthetized by the neuroblastoma PDX cells revealed that laminin α5 chain was highly expressed in both LU-NB-2 and LU-NB-3 (Supplementary Fig. S4a). We therefore tested recombinant human laminin 511 (LN-511) and 521 (LN-521) as substrates for the PDX cells. Though both laminin isoforms promoted adherent growth of LU-NB-2 and LU-NB-3, we used LN-521 for further experiments. Following adherent growth on LN-521, PDX cells again formed spheres when transferred back to uncoated dishes (Fig. 5a). As laminin α5 was significantly upregulated in serum-grown LU-NB-3 cells (Supplementary Fig. S4b) and PDX cells adhering to LN-511 or LN-521 showed signs of morphological differentiation, we asked whether surface adherence alone could
Figure 3. Serum promotes neuronal development, downregulation of MYCN activity and telomerase complex components in PDX cells. LU-NB-3 cells were cultured in stem cell (SC) medium or 10% serum for 7 days unless other specified. (a) Heatmap showing the top 100 varying genes across all samples. (b) Gene ontology analysis showing significantly enriched terms from the top 3 ontology clusters enriched in 10% serum cultured LU-NB-3 cells. Dashed line indicates Benjamini p-value < 0.05 (full list of ontologies provided in Supplementary File S1). (c,d) Boxplots of a neuronal differentiation score based on Fredlund et al.2 (c) and MYCN expression levels (d). (e) GSEA of MYCN target genes based on a ranked gene list of all genes according to differential expression between the two culture conditions. (f) MYCN western blot after 10058-F4 treatment (72 h). (g) mRNA expression of differentiation markers and NOTCH1 after 10058-F4 treatment (72 h). (h) Boxplots showing expression of telomerase complex proteins (DKC1, GAR1 and NHP2) as well as the RNA subunit TERC and the enzymatic subunit TERT, in different culture conditions. Error bars represent ± SEM from 3 independent experiments. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001; Student’s t test.
induce a differentiated phenotype. PDX cells grown on LN-521 showed a modest increase in \textit{TH}, \textit{CHGA} and \textit{SYP} expression (Fig. 5b and Supplementary Fig. S4c) as compared to serum-grown PDX cells (e.g. compare 3.4-fold increase in \textit{TH} expression in Fig. 5b and 17.9-fold increase in Fig. 2b). At the protein level, \textit{TH} and \textit{GAP43} levels

**Figure 4.** Serum-induced differentiation of PDX cells is suppressed by stem cell growth factors and is reversible. (a,b) LU-NB-3 cells grown in presence of serum or growth factors as indicated. (a) Live cells determined by trypan blue staining (72 h). (b) mRNA expression of \textit{MYCN} and \textit{TH} levels. (c) LU-NB-3 cells grown in stem cell (SC) medium or 10% charcoal-stripped serum (ccsSerum). Scale bars, 100 μm. (d,e) mRNA (d) and protein (e) expression of neuronal markers and \textit{MYCN}. (f) The serum-induced differentiation is reversible. (f) Culture conditions for LU-NB-3 cells. (g) Live (red bars) and dead cells (white bars) determined by trypan blue staining after culture conditions specified in (f). (h) mRNA expression of \textit{MYCN}, \textit{TERT} and neuronal markers after culture conditions specified in (f). (i) Western blotting of neuronal markers after culture conditions specified in (f). Error bars represent ± SEM from 3 independent experiments. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001; Student’s t test.
Figure 5. Laminin promotes viability of neuroblastoma PDX cells and maintains tumorigenic and metastasizing capacity without inducing differentiation. LU-NB-3 cells were grown as spheres in stem cell (SC) medium or adherently on laminin (LN-521) for 72 h (a–g). (a) Cells grown as spheres in SC medium (top panel), adherently on LN-521 (middle panel) and as spheres after laminin-growth (lower panel). Scale bars, 100 μm. (b,c) Expression of neuronal markers, MYCN and TERT at mRNA level (b) and protein level (c) in LU-NB-3 cells. (d) Live (blue bars) and dead cells (white bars) as determined by trypan blue staining of sphere or laminin cultures (72 h). (e,f) IHC staining of tumors (e) and metastases to the liver, lung and bone marrow (BM) (f) formed by injected long-term LN-521-cultured LU-NB-3 cells. Scale bars, 100 μm. (g) Cell viability of sphere or LN-521-cultured LU-NB-3 cells after 72 h treatment with cisplatin, doxorubicin and etoposide at various concentrations. Drugs were added 24 h after seeding. Error bars represent ± SEM from 3 independent experiments. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001; Student’s t test.
slightly increased in LN-521-cultured LU-NB-2 and LU-NB-3 cells, while CHGA was downregulated, despite its increased mRNA expression (Fig. 5c and Supplementary Fig. S4d). In addition, the expression of genes associated with a less differentiated phenotype was not affected by laminin growth (Supplementary Fig. S4e). Monolayer culture provides uniform access to growth factors and LN-521–cultured LU-NB-3 cells were more viable than sphere-grown cells (Fig. 5d). MYCN expression did not differ between LN-521–cultured and sphere-cultured LU-NB-3 cells (Fig. 5b), although it was slightly lower in LN-521–cultured LU-NB-2 cells (Supplementary Fig. S4c). Importantly, TERT levels were unaffected in LN-521–cultured PDX cells (Fig. 5b and Supplementary Fig. S4c). In conclusion, neuroblastoma PDX cells can grow adherently on laminin, which promotes the viability of the cells with little effect on differentiation. As anticipated, addition of serum to LN-521–cultured cells promoted differentiation (Supplementary Fig. S5a,b).

To determine whether PDX cells cultured on LN-521 maintained tumor-initiating and metastatic capacities, we cultured cells on LN-521 for 3 months before injecting cells orthotopically into the adrenal gland of NSG mice. All animals (n = 6) developed tumors with typical neuroblastoma morphology and examination of lungs, liver and bone marrow revealed metastatic growth in all examined animals (Fig. 5e,f). Finally, the response to various cytotoxic drugs did not differ between sphere- and LN-521–cultured cells (Fig. 5g and Supplementary Fig. S4f), suggesting that laminin adherent cells are promising models for future drug screening.

Discussion

Conventional tumor-derived cell lines established decades ago, including neuroblastoma cell lines, have traditionally been cultured in the presence of serum. Although derived from highly aggressive and metastatic tumors they show limited infiltrative growth in rodent xenograft models and generally do not metastasize. We previously established and characterized orthotopic neuroblastoma PDX models and showed that PDX tumors infiltrated adjacent tissues and seeded metastases to liver, lungs, and bone marrow. Such patterns of infiltrative growth and metastases are not observed with orthotopically xenografted conventional cell lines48. We further showed that neuroblastoma cells isolated from PDXs could be cultured short-term as spheres, and when re-injected they formed tumors and metastases10,11. Here, we show that these cells retain their proliferative capacity after long-term passaging, suggesting that they have infinite in vitro growth capacity. The PDX cell lines retain patient-specific genomic aberrations up to at least 30 passages without obtaining additional gross DNA aberrations. Furthermore, their tumorigenic and metastatic capacities are retained also at high in vitro passages. We further demonstrate that the sphere-forming PDX cell lines can be grown as a monolayer on LN-521 without compromising their capacities to form tumors and metastases. Importantly, PDX cells adhering to LN-521 did not significantly alter the cellular response to cytotoxic drugs. As the neuroblastoma PDX tumors are established from high-risk tumors and metastasize to clinically relevant sites, including the bone marrow, the neuroblastoma PDX model offers a highly promising in vivo model for pre-clinical drug testing. We further conclude that PDX cells grown as spheres or on LN-521 are suitable in vitro systems for future screening of drugs targeting aggressive neuroblastoma.

Further analysis of PDX cells grown on LN-521 revealed that they were slightly more viable and expanded readily as compared to sphere-grown cells, suggesting that laminin-integrin signaling supports neuroblastoma PDX cell survival. Intriguingly, the PDX cells readily attached to two laminin isoforms containing the α5 chain, laminin 511 and 521; the same type of laminins used for growing embryonal stem cells29,30. This may suggest that the neuroblastoma PDX cells share features with cells of embryonal origin. Recent work comparing glioma cells grown as neurospheres versus those grown on laminin, showed no significant differences in growth rate, apoptosis, differentiation markers or tumorigenicity31. These findings together with our results support that both growth conditions are suitable for stable expansion of neural-derived tumor cells in vitro.

We found that withdrawal of EGF and bFGF and addition of serum also promoted attachment of the PDX cells but led to differentiation, reduced MYCN levels and decreased proliferation. Thus, avoiding serum appears to be a key strategy to preserve the original immature features of these neuroblastoma cells which is in line with previously established primary neuroblastoma cells propagated in serum-free media32. Differentiation is highly associated with neuroblastoma patient outcome, and it has been proposed that malignant transformation of neuroblasts at different stages during fetal development causes the great phenotypic diversity of this disease32. The enigmatic spontaneous differentiation observed in stage 4S neuroblastomas, together with experimentally induced in vitro differentiation of neuroblastoma cells43 raised hope that aggressive neuroblastomas could be treated by triggering neuronal differentiation. In the clinic, high-risk neuroblastoma patients are treated with the differentiating agent isotretinoin to combat minimal residual disease, however whether the effect of this treatment is due to induced tumor cell differentiation in patients has not been demonstrated. Furthermore, so far, there are no studies demonstrating that neuroblastoma cells in culture established from high-risk patients can terminally differentiate (i.e. acquire an irreversibly differentiated phenotype and ceased proliferation capacity). Here we show that the serum-induced overt morphological differentiation accompanied by increased and robust expression of marker genes is reversible. Furthermore, despite the serum-differentiated PDX cells expressing the neurotrophin receptors TrkC and TrkA, which mediate the key responses leading to terminally differentiated sympathetic neurons48, no additive effect was observed when combining serum with the neurotrophins NT-3 and NGF. We conclude that the neuroblastoma PDX cells can be pushed to a more differentiated phenotype; however, they appear to have lost the capacity to terminally differentiate (Fig. 6).

Prolonged culture of LU-NB-3 cells in serum did not result in a regained high growth rate. Whether the PDX cells could be established as classical cell lines in serum-containing medium when cultured for longer periods remains to be shown. Although it would be of academic interest to try to establish PDX cells in serum-medium to compare geno- and phenotypes with PDX cells cultured in SC medium, such cell lines would be of less value for understanding the biology of neuroblastoma. Based on our own observations and on similar findings reported in glioma4, we expect that such cells will phenotypically and genotypically deviate from the tumors they were...
derived from. Theoretically, serum-grown cells experience cellular crisis similar to what happens in tumor cells upon loss of telomerase activity. Reduced telomerase activity in neuroblastoma cells resulted in increased frequency of anaphase-bridges\(^23\). Thus, upon re-activation of telomerase activity and recovered proliferative capacity, long-term serum-grown cells have likely gained additional genetic aberrations, created by breakage-fusion-bridge cycles.

Considering the significance of \(\text{MYCN}\) in neuroblastoma, our observation that \(\text{MYCN}\) was the top downregulated transcript in serum-grown PDX cells is intriguing. As well as being essential for normal neurogenesis\(^33\), \(\text{MYCN}\) has been shown to prevent neuronal differentiation\(^26\), \(^34\), \(^35\), although overexpression of \(\text{MYCN}\) in \(\text{non-MYCN}\)-amplified SK-N-SH cells did not impede differentiation induced by several different protocols\(^36\). Treatment with the \(\text{MYC-MAX}\) inhibitor 10058-F4 promoted expression of a few, but not all of the differentiation markers tested, showing that \(\text{MYCN}\) inhibition alone cannot substantially push the PDX cells towards a more differentiated stage. We speculate that presence of EGF and bFGF hinders differentiation to some extent. It would therefore be interesting to test 10058-F4 without the addition of growth factors. However, withdrawal of growth factors in itself leads to downregulation of \(\text{MYCN}\), making it difficult to draw conclusions from that type of experiment.

It was recently shown that \(\text{MYCN}\)-regulated miRNAs inhibit the expression of several nuclear hormone receptors, including the glucocorticoid hormone receptor, and simultaneous inhibition of \(\text{MYCN}\) and activation of glucocorticoid signaling resulted in differentiation of neuroblastoma cells\(^25\). Our data show that charcoal-stripped serum devoid of steroids promoted \(\text{MYCN}\) downregulation and increased the expression of differentiation markers in the PDX cells, however it did not promote attachment or morphological differentiation.
In conclusion, we show that neuroblastoma PDX cells grown under serum-free conditions maintain patient-specific genomic aberrations over time and that tumorigenic and metastatic capabilities, as well as response to cytotoxic drugs, are preserved also at higher in vitro passages or when cells are cultured as monolayer on laminin. Our data and other studies showing serum-induced differentiation of tumor cells4,32 strongly suggest that serum should be avoided in order to maintain tumor cell immaturity in culture. The phenotypic effects of serum have mostly been overlooked but they can explain why serum-established cell lines do not metastasize or grow invasively in xenograft models. This observation could account for the generally poor translation of results from pre-clinical screening based on classical cell lines to clinical testing of drugs4.

Materials and Methods

Neuroblastoma PDX cells, cell lines and cell culture treatments. Tissue from neuroblastoma PDXs was dissociated and digested for 45 min at 37°C with Liberase (0.15 mg/mL, Roche), passed through a 70 µm cell strainer (BD Biosciences) and cultured in stem cell medium (SC medium) at 37°C in 5% CO2. Spheres were dissociated using Accutase (Sigma-Aldrich, St. Louis, MO). PDX #2 had been established from cerebral metastasis from a stage 4 tumor where the patient had undergone prior treatment while PDX #3 had been established from a primary stage 3 tumor in the adrenal gland. For serum culture, SC medium excluding growth factors and B-27 supplement was supplemented with fetal bovine serum (FBS) or 10% charcoal-stripped FBS (Thermo Scientific). For monolayer culture on human recombinant laminin (Biolamina), plates were coated according to manufacturers instructions. PDX cells were routinely grown to confluence and dissociated using Accutase. The neuroblastoma cell line SK-N-BE(2)c (ATCC) was cultured as previously described18. All cells were routinely screened for mycoplasma and authentication was performed by SNP profiling of SK-N-BE(2)c cells, PDX cells and corresponding PDX (Multiplexion, Germany).

Treatment with MYC-MAX inhibitor 10058-F4 (Sigma) was performed for 72 h at 60 µM or 75 µM. Treatment with neurotrophins was done for 4 days with nerve growth factor (NGF, 50 ng/ml, PeproTech), neurotrophin-3 (NT-3, 50 ng/ml, PeproTech), or a combination. Prior to neurotrophin treatment, cells were cultured in SC medium, 2% or 10% serum for 7 days. For cytostatic treatments, cells were treated with cisplatin, doxorubicin or etoposide in BRAND® 96-well plates directly after seeding or 48 h post-seeding. CellTiter-Glo Luminescent Cell Viability Assay (Promega) was used to determine cell viability 72 h post-treatment. Cell culture images were captured with a Carl Zeiss AxioCam IC microscope and the ZEN software.

Quantitative real-time PCR. Total RNA was extracted using the RNeasy Micro Kit (Qiagen). Complementary DNA and qRT-PCR was performed as described previously38. Three housekeeping genes (SDHA, UBC, YWHAZ) were used to normalize gene expression. Primer sequences are given upon request.

Western blotting. Cells were lysed in RIPA buffer supplemented with complete protease inhibitor. Proteins were separated by SDS-PAGE and transferred to HyBond-C Extra nitrocellulose membranes. The following antibodies were used: CHGA (M0869, Dako), TH (Ab112, Abcam), N-MYC (Sc-791, Santa Cruz BioTechnology), SYT (M0776, Dako), GAP43 (8945, Cell Signaling), Actin (691001, MP Biomedicals), and SDHA (Ab14715, Abcam).

Cell cycle analysis. Cell cycle distribution was determined by fixating PDX cells in 70% ice-cold ethanol in −20°C, washed in PBS and incubated on ice for 45 min in Vindelöv solution (3.5 µmol/L Tris-HCl (pH 7.6), 10 mmol/L NaCl, 50 µg/mL propidium iodide, 20 µg/mL RNase, 0.1% v/v NP40). Samples were run on a FACSVerse instrument (BD Biosciences) and data was analyzed using Flowjo software (Flowjo, LLC).

Single nucleotide polymorphism array. DNA was extracted from PDX cells at low (p3), middle (p15) and high (p30) in vitro passages using DNeasy Blood and Tissue Kit (Qiagen). For analysis, genomic DNA was hybridized to an Affymetrix CytoScan HD chip (Affymetrix) containing approximately 2.6 million markers of which almost 750,000 are SNPs. Constitutional copy number variants were removed by filtering against the Database of Genomic Variants (Oct. 2016). Copy number variation analyses were performed using ChAS software. The analyses of xenografts and the corresponding patient tumors were reported previously10.

RNA sequencing and data analysis. PDX cells were cultured in SC medium or 10% serum for 7 days. Total RNA was extracted using the RNeasy Mini Kit (Qiagen) and RIN values were checked using an Agilent 2100 Bioanalyzer (Agilent). RNA-Seq analysis was performed on an Ion Proton System for next-generation sequencing (Thermo Fischer). For each of the samples, 10 ng of total RNA was reverse transcribed using the Ion AmpliSeq Transcriptome Human Gene Expression kit (Revision A.0) following the protocol of the manufacturer (Thermo Fisher) and as previously described18.

Sequences were aligned to hg19 AmpliSeq Transcriptome ERCC v1 and were quantified on gene level. Gene level reads were normalized according to total number of reads per sample. Data was analyzed using R statistical language (version 3.1.1). Genes with zero variance were removed from the data. The neuronal differentiation signature score was calculated as described by Fredlund and colleagues2. Differential expression was determined using unpaired t-test analysis in R using the ‘stats’ package (version 3.3.2). Gene Ontology (GO) analyses were performed on the top 250 upregulated genes in serum treated samples, using the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.8 tool41. A complete gene list of all genes present in the RNA sequencing data was used as the experimental background for GO analyses. Gene set enrichment analyses (GSEA)41 was performed on a ranked list of all genes based on differential expression (t-statistic) between SC and 10% serum treatments using the c2.all.v5.0 curated gene set collection (Broad Institute MSigDB).
Animal procedures. Four- to six-week-old female or male NSG mice were purchased from Charles River (Charles River Laboratories). Mice were housed under pathogen-free conditions and received autoclaved water and food. Orthotopic injections of PDX cells were performed as previously described\(^\text{[20]}\). All animal procedures followed the guidelines set by the Malmö-Lund Ethical Committee and the use of laboratory animals and were conducted in accordance with European Union directive on the subject of animal rights. Experimental protocols were approved by the Malmö-Lund Ethical Committee (ethical permits M146-13 and M11-15). The establishment of neuroblastoma PDXs was approved by the regional ethical review board at Lund University (Dnr. 2011/289) and written informed consent was obtained.

Immunohistochemistry. Xenograft tumors and mice organs were fixed in formalin and bone specimens were decalcified in 10% EDTA (pH 8). Following paraffin embedding, 4 μm tissue sections were stained using AutostainerPlus (Dako). The following antibodies were used: NCAM (Leica Biosystems, NCL-L-CD56-504), Ki67 (MIB-1, Dako), and TH (Ab112, Abcam). Images were acquired using Olympus BX63 microscope and DP80 camera along with the CellSense Dimension imaging software.

Statistical analysis. All values are reported as mean ± SEM from at least three independent experiments unless otherwise stated. The two-sided Student unpaired t test was used for statistical analyses, and three levels of significance were used: *P < 0.05; **P < 0.01; ***P < 0.001.

Data Availability. All data generated or analyzed during this study are included in this published article (and its Supplementary Information files).

References

1. Pinto, N. R. et al. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol 33, 3008–3017, doi:10.1200/JCO.2014.59.4668 (2015).
2. Fredlund, E., Ringner, M., Maris, J. M. & Pahlman, S. High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci USA 105, 14094–14099, doi:10.1073/pnas.0804455105 (2008).
3. Cohn, S. L. et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 27, 289–297, doi:10.1200/JCO.2008.16.6785 (2009).
4. Gillet, J. P., Varma, S. & Gottesman, M. M. The clinical relevance of cancer cell lines. Eur J Cancer 44, 447–457, doi:10.1016/j.ejca.2007.05.004 (2008).
5. Li, A. et al. Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res 6, 207–225, doi:10.1158/1541-7786.MCR-07-0280 (2008).
6. Thiele, C. J. Neuroblastoma Cell Lines. In (Ed.) Masters, J. Human Cell Culture. Lancaster, UK: Kluwer Academic Publishers, 1, 21–53 (1998).
7. Hidalgo, M. et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 4, 998–1013, doi:10.1158/2159-8290.CD-14-0001 (2014).
8. Hoffman, R. M. Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. Nature Reviews Cancer 15, 451–452, doi:10.1038/nrc3972 (2015).
9. Braeckeveldt, N. et al. Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours. International journal of cancer. Journal international du cancer 136, E252–261, doi:10.1002/ijc.29217 (2015).
10. Braeckeveldt, N. et al. Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours. Cancer Lett 375, 384–389, doi:10.1016/j.canlet.2016.02.046 (2016).
11. Bate-Eya, L. T. et al. Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours. Eur J Cancer 50, 628–637, doi:10.1016/j.ejca.2013.11.015 (2014).
12. Ross, R. A., Walton, J. D., Han, D., Guo, H. F. & Cheung, N. K. A distinct gene expression signature characterizes human neuroblastoma stem cells. Stem Cell Res 15, 419–426, doi:10.1016/j.scr.2015.08.008 (2015).
13. Weiler, R. et al. Divergent changes of chromogranin A/secretogranin II levels in differentiating human neuroblastoma cells. FEBS Lett 265, 27–29 (1990).
14. Hoehner, J. C. et al. A developmental model of neuroblastoma: differentiating stroma-poor tumors’ progress along an extra-adrenal chromafin lineage. Lab Invest 75, 659–675 (1996).
15. Pahlman, S. & Hoehner, J. C. Neurotrophin receptors, tumor progression and tumor maturation. Mol Med Today 2, 432–438 (1996).
16. Nagakawa, A. et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 328, 847–854, doi:10.1056/NEJM199303253281205 (1993).
17. Kogner, P. et al. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res 53, 2044–2050 (1993).
18. Lavenius, E., Gestblom, C., Johansson, I., Nanberg, E. & Pahlman, S. Transfection of TRK-A into human neuroblastoma cells restores their ability to differentiate in response to nerve growth factor. Cell Growth Diff 6, 727–736 (1995).
19. Edsjö, A. et al. Differences in early and late responses between neurotrophin-stimulated trkA- and trkC-transfected SH-SYSY neuroblastoma cells. Cell Growth Diff 12, 39–50 (2001).
20. Pahlman, S., Odelstad, L., Larsson, E., Grotte, G. & Nilsson, K. Phenotypic changes of human neuroblastoma cells in culture induced by 12-O-tetradecanoyl-phorbol-13-acetate. International journal of cancer. Journal international du cancer 28, 583–589 (1981).
21. Zhao, Y., Cheng, D., Wang, S. & Zhu, J. Dual roles of c-Myc in the regulation of hTERT gene. Nucleic Acids Res 42, 10385–10398, doi:10.1093/nar/gku721 (2014).
22. von Stegink, K. et al. snoRNPs Regulate Telomerase Activity in Neuroblastoma and Are Associated with Poor Prognosis. Transl Oncol 6, 447–457 (2013).
23. von Stegink, K. et al. Individual patient risk stratification of high-risk neuroblastomas using a two-gene score suited for clinical use. International journal of cancer. Journal international du cancer, doi:10.1002/ijc.29461 (2015).
24. Conil, I. et al. Niche-independent symmetrical self-renewal of a mammalian tissue stem cell. PLoS Biol 3, e283, doi:10.1371/journal.pbio.0030283 (2005).
25. Ribeiro, D. et al. Regulation of Nuclear Hormone Receptors by MYCN-Driven miRNAs Impacts Neural Differentiation and Survival in Neuroblastoma Patients. Cell Rep 16, 979–993, doi:10.1016/j.celrep.2016.06.052 (2016).
26. Pöllard, S. M. et al. Glial stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell stem cell 4, 568–580, doi:10.1016/j.stem.2009.03.014 (2009).
34. Kang, J. H.
35. Alam, G.
32. Cooper, M. J.
41. Subramanian, A.
39. Osman, A., Hitzler, W. E., Ameur, A. & Provost, P. Differential Expression Analysis by RNA-Seq Reveals Perturbations in the Platelet
36. Edsjo, A.
31. Rahman, M.
40. Dennis, G. Jr.
30. Rodin, S., Antonsson, L., Hovatta, O. & Tryggvason, K. Monolayer culturing and cloning of human pluripotent stem cells on
29. Rodin, S.
28. Sun, Y. et al. Long-term tripotent differentiation capacity of human neural stem (NS) cells in adherent culture. Mol Cell Neurosci 38, 245–258, doi:10.1016/j.mcn.2008.02.014 (2008).
29. Rodin, S. et al. Long-term self-renewal of human pluripotent stem cells on human recombinant laminin-511. Nat Biotechnol 28, 611–615, doi:10.1038/nbt.1620 (2010).
30. Rodin, S., Antonsson, L., Hovatta, O. & Tryggvason, K. Monolayer culturing and cloning of human pluripotent stem cells on laminin-521-based matrices under xeno-free and chemically defined conditions. Nat Protoc 9, 2354–2368, doi:10.1038/nprot.2014.159 (2014).
31. Rahman, M. et al. Neurosphere and adherent culture conditions are equivalent for malignant glioma stem cell lines. Anat Cell Biol 48, 25–35, doi:10.5115/ach.2015.48.1.25 (2015).
32. Cooper, M. J. et al. Human neuroblastoma tumor cell lines correspond to the arrested differentiation of chromaffin adrenal medullary neuroblasts. Cell Growth Differ 1, 149–159 (1990).
33. Knospiter, P. S., Cheng, P. F. & Eisenman, R. N. N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev 16, 2699–2712, doi:10.1101/gad.1021202 (2002).
34. Kang, J. H. et al. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochemical and biophysical research communications 351, 192–197, doi:10.1016/j.bbrc.2006.10.020 (2006).
35. Alam, G. et al. MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development. Am J Pathol 173, 856–866, doi:10.2353/apth.2009.090019 (2009).
36. Edsjo, A. et al. Neuroblastoma cells with overexpressed MYCN retain their capacity to undergo neuronal differentiation. Lab Invest 84, 406–417, doi:10.1038/labinvest.3700661 (2004).
37. Ricci-Vitiani, L. et al. Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111–115, doi:10.1038/ nature05384 (2007).
38. Mohlin, S. et al. PI3K-mTORC2 but not PI3K-mTORC1 regulates transcription of HIF2A/EPAS1 and vascularity in neuroblastoma. Cancer Res 75, 4617–4628, doi:10.1158/0008-5472.CAN-15-0708 (2015).
39. Osman, A., Hitzler, W. E., Ameur, A. & Provost, P. Differential Expression Analysis by RNA-Seq Reveals Perturbations in the Platelet mRNA Transcriptome Triggered by Pathogen Reduction Systems. PLoS One 10, e0133070, doi:10.1371/journal.pone.0133070 (2015).
40. Dennis, G. I. et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4, P3 (2003).
41. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102, 15545–15550, doi:10.1073/pnas.0506580102 (2005).

Acknowledgements
We thank Ms. Siv Beckman and Mr. Javanshir Esfandyari for expert technical assistance, and professor Graeme Eisenhofer and Ms. Denise Kaden for performing steroid profiling. The authors acknowledge the support of the National Genomics Infrastructure (NGI)/Uppsala Genome Center and UPPMAX for providing assistance in massive parallel sequencing and computational infrastructure. Work performed at NGI/Uppsala Genome Center has been funded by RFI/VR and Science for Life Laboratory, Sweden. This work was supported by the Swedish Childhood Cancer Foundation, the Swedish Cancer Society, the Swedish Research Council, Fru Berta Kamprad's Foundation, Hans von Kantzow’s Foundation, The Gyllenstierna Krapperup's Foundation, The Royal Physiographic Society in Lund, the Strategic Cancer Research Program BioCARE, Gunnar Nilsson's Cancer Foundation, Region Skåne and the research funds of Skåne University Hospital.

Author Contributions
C.U.P., M.M. and C.W. performed experiments. C.U.P., S.P. and C.W. designed the research and wrote the manuscript. K.V. performed procedures. N.B. performed PDX procedures. N.B. provided PDX material. D.G. performed SNP analyses. M.A.H. provided expertise on experiments regarding MYCN. C.W. supervised the project. All authors reviewed the manuscript.

Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-09662-8

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017